A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4

被引：0
|
作者：
Tian, Meijie
Jia, Katrina
Wu, Jerry T.
Wei, Jun S.
Cheuk, Adam T.
Zhang, Zhongmei
Pope, Eleanor G.
Shor, Boris
Tumey, L. Nathan
Khan, Javed
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB042
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Developing FGFR4 Chimeric Antigen Receptor CAR T Cell Therapy Against Rhabdomyosarcoma
    Shivaprasad, Nityashree
    Xiong, Ying
    Yohe, Marielle
    Schneider, Dina
    Shern, Jack
    Baskar, Sivasubramanian
    Dimitrov, Dimiter
    Sorenson, Paul
    Orentas, Rimas
    Khan, Javed
    MOLECULAR THERAPY, 2016, 24 : S257 - S258
  • [12] Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
    Tian, Meijie
    Wei, Jun S.
    Shivaprasad, Nityashree
    Highfill, Steven L.
    Gryder, Berkley E.
    Milewski, David
    Gryder, Berkley
    Brown, G. Tom
    Moses, Larry
    Song, Hannah
    Wu, Jerry T.
    Azorsa, Peter
    Kumar, Jeetendra
    Schneider, Dina
    Chou, Hsien-Chao
    Song, Young K.
    Rahmy, Abdelrahman
    Masih, Katherine E.
    Kim, Yong Yean
    Belyea, Brian
    Linardic, Corinne M.
    Dropulic, Boro
    Sullivan, Peter M.
    Sorensen, Poul H.
    Dimitrov, Dimiter S.
    Maris, John M.
    Mackall, Crystal L.
    Orentas, Rimas J.
    Cheuk, Adam T.
    Khan, Javed
    CELL REPORTS MEDICINE, 2023, 4 (10390)
  • [13] FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma
    Sullivan, Peter M.
    Kumar, Rajesh
    Li, Wei
    Hoglund, Virginia
    Wang, Lingyan
    Zhang, Yue
    Shi, Megan
    Beak, Dusan
    Cheuk, Adam
    Jensen, Michael C.
    Khan, Javed
    Dimitrov, Dimiter S.
    Orentas, Rimas J.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (10) : 1608 - 1621
  • [14] FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
    Quintanal-Villalonga, Alvaro
    Ferrer, Irene
    Guruceaga, Elizabeth
    Cirauqui, Cristina
    Marrugal, Angela
    Ojeda, Laura
    Garcia, Santiago
    Zugazagoitia, Jon
    Munoz-Galvan, Sandra
    Lopez-Rios, Fernando
    Montuenga, Luis
    Vicent, Silvestre
    Molina-Pinelo, Sonia
    Carnero, Amancio
    Paz-Ares, Luis
    EBIOMEDICINE, 2020, 53
  • [15] FGFR4 and CD276 dualtargeting CAR-T cells for treating rhabdomyosarcoma and other solid tumors
    Tian, Meijie
    Cheuk, Adam
    Milewski, David
    Wei, Jun S.
    Chou, Hsien-Chao
    Kim, Yong Yean
    Song, Young K.
    St Croix, Brad
    Ho, Mitchell
    Khan, Javed
    CANCER RESEARCH, 2022, 82 (12)
  • [16] A CXCR4-Targeted Site-Specific Antibody-Drug Conjugate
    Kularatne, Sumith A.
    Deshmukh, Vishal
    Ma, Jennifer
    Tardif, Virginie
    Lim, Reyna K. V.
    Pugh, Holly M.
    Sun, Ying
    Manibusan, Anthony
    Sellers, Aaron J.
    Barnett, Richard S.
    Srinagesh, Shailaja
    Forsyth, Jane S.
    Hassenpflug, Wolf
    Tian, Feng
    Javahishvili, Tsotne
    Felding-Habermann, Brunhilde
    Lawson, Brian R.
    Kazane, Stephanie A.
    Schultz, Peter G.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2014, 53 (44) : 11863 - 11867
  • [17] Anti-myeloid poly-pharmacy allows FGFR4-targeted chimeric antigen receptors to effectively treat an orthotopic model of rhabdomyosarcoma
    Sullivan, Peter M.
    Kumar, Rajesh
    Li, Wei
    Wang, Lingyang
    Zhang, Yue
    Jamet, Sophie
    Cheuk, Adam
    Khan, Javed
    Dimitrov, Dimiter S.
    Orentas, Rimas J.
    CANCER RESEARCH, 2022, 82 (12)
  • [18] FGFR1 and FGFR4 oncogenicity depends on N-Cadherin and their co-expression may predict FGFR-targeted therapy efficacy (vol 53, 102, 2021)
    Xiang, Qian
    Kang, Liang
    Wang, Juntan
    Liao, Zhiwei
    Song, Yu
    Zhao, Kangcheng
    Wang, Kun
    Yang, Cao
    Zhang, Yukun
    EBIOMEDICINE, 2021, 66
  • [19] Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma (vol 5, 101586, 2024)
    Tian, Meijie
    Wei, Jun S.
    Shivaprasad, Nityashree
    Highfill, Steven L.
    Gryder, Berkley E.
    Milewski, David
    Brown, G. Tom
    Moses, Larry
    Song, Hannah
    Wu, Jerry T.
    Azorsa, Peter
    Kumar, Jeetendra
    Schneider, Dina
    Chou, Hsien-Chao
    Song, Young K.
    Rahmy, Abdelrahman
    Masih, Katherine E.
    Kim, Yong Yean
    Belyea, Brian
    Linardic, Corinne M.
    Dropulic, Boro
    Sullivan, Peter M.
    Sorensen, Poul H.
    Dimitrov, Dimiter S.
    Maris, John M.
    Mackall, Crystal L.
    Orentas, Rimas J.
    Cheuk, Adam T.
    Khan, Javed
    CELL REPORTS MEDICINE, 2024, 5 (05)
  • [20] FGFR1 and FGFR4 oncogenicity depends on N-Cadherin and their co-expression may predict FGFR-targeted therapy efficacy (vol 53, pg 102, 2021)
    Xiang, Qian
    Kang, Liang
    Wang, Juntan
    Liao, Zhiwei
    Song, Yu
    Zhao, Kangcheng
    Wang, Kun
    Yang, Cao
    Zhang, Yukun
    EBIOMEDICINE, 2021, 66
12345